Sanofi Genzyme retreats from its Parkinson’s deal with gene therapy upstart Voyager, part of an $845M pact
Voyager $VYGR plans to launch a pivotal study of its leading gene therapy for Parkinson’s disease before the end of the year, but they won’t be doing it with Sanofi Genzyme as a partner.
The Cambridge, MA-based biotech says that Sanofi Genzyme opted not to pick up the option outlined in their $845 million deal, evidently because it didn’t include US rights.
Voyager’s shares drop 19% in after-market trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
